← Back to Search

Regional Anesthesia for Broken Arm

Phase 4
Recruiting
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Fractures treated with open reduction percutaneous pinning requiring fixation
Isolated lateral condyle humerus fracture
Must not have
Pathologic fractures
Swelling requiring post-operative hospitalization for monitoring
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after surgery. until the patient returns to first post-operative visit, 7-10 days post-operatively, assess up to 10 days.
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial is testing if a numbing injection near the collarbone can better control pain in children aged 4-12 who have specific elbow fractures and need surgery. The injection blocks pain signals from the arm to the brain. The goal is to see if this method reduces the need for pain medicine after surgery.

Who is the study for?
This trial is for children with a specific type of broken arm (isolated lateral condyle humerus fracture) that needs surgery to fix it. They must not have other injuries, allergies to ropivacaine or oxycodone, open fractures, swelling needing hospital stays after surgery, or conditions affecting their ability to rate pain using facial expressions.
What is being tested?
The study compares two ways to manage pain after arm fracture surgery in kids. One group gets a nerve block before surgery; the other follows standard care. Both get oxycodone afterwards. Pain and satisfaction are checked using scales and questionnaires over about one week.
What are the potential side effects?
Possible side effects include reactions at the puncture site from the nerve block or dressing application and any known side effects of ropivacaine like numbness or weakness in the area where it's given.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery to fix a broken bone with pins.
Select...
I have a fracture in the outer part of my elbow bone.
Select...
My elbow fracture is classified as a type II or III lateral condyle with more than 2mm displacement.
Select...
I have a specific type of elbow fracture.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had fractures due to my disease.
Select...
I was hospitalized for swelling after surgery.
Select...
I have a broken bone with related nerve or blood vessel damage.
Select...
I am allergic to ropivacaine or oxycodone.
Select...
I have a broken bone that is exposed through my skin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after surgery. until the patient returns to first post-operative visit, 7-10 days post-operatively, assess up to 10 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after surgery. until the patient returns to first post-operative visit, 7-10 days post-operatively, assess up to 10 days. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Wong-Baker FACES Pain Scale-Revised (FPSR)
Secondary study objectives
Total Quality Pain Management (TQPM) Instrument: 30 question questionnaire
Other study objectives
Pain Medication Logs (Amount Taken)
Pain Medication Logs (Side Effects)

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Infraclavicular Regional BlockExperimental Treatment1 Intervention
This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
Group II: Puncture WoundPlacebo Group1 Intervention
This group is given the same puncture wound and dressing given to the experimental group.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ropivacaine
FDA approved

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Infraclavicular nerve blocks, a form of regional anesthesia, work by injecting local anesthetics near the brachial plexus to block pain signals from the affected extremity. This method prevents the transmission of pain signals to the brain, providing effective pain relief. Other common treatments include systemic analgesics like opioids, which bind to opioid receptors in the brain and spinal cord to reduce pain perception, and nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit enzymes involved in inflammation and pain. For pain patients, understanding these mechanisms is crucial as it helps in selecting the most appropriate and effective pain management strategy, potentially reducing the need for systemic medications and their associated side effects.
A randomized comparison between ultrasound-guided costoclavicular and infraclavicular block for upper extremity surgeryA randomized comparison between costoclavicular and paracoracoid ultrasound-guided infraclavicular block for upper limb surgery.Comparing vertical and coracoid approaches for infraclavicular block in orthopedic surgery of the forearm and hand.

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,567 Previous Clinical Trials
10,267,024 Total Patients Enrolled
9 Trials studying Pain
1,312 Patients Enrolled for Pain

Media Library

Ropivacaine Clinical Trial Eligibility Overview. Trial Name: NCT03796572 — Phase 4
Pain Research Study Groups: Infraclavicular Regional Block, Puncture Wound
Pain Clinical Trial 2023: Ropivacaine Highlights & Side Effects. Trial Name: NCT03796572 — Phase 4
~1 spots leftby Jan 2025